Department of Surgery, Yokohama City University, Yokohama, Japan
Department of Surgery, Yokohama City University, Yokohama, Japan.
In Vivo. 2020 Jul-Aug;34(4):2021-2027. doi: 10.21873/invivo.12001.
BACKGROUND/AIM: The aim of the present study was to evaluate the optimal number of harvested LNs (LNs) in patients who were LN metastasis-negative after curative esophagectomy for esophageal cancer.
Sixty-one patients who underwent curative surgery for esophageal cancer between 2005 and 2017 and diagnosed as lymph node metastasis-negative were included in this study.
The 5-year overall survival rates were 27.8% for 0-20 harvested LNs, 35.7% for 21-30 harvested LNs, 79.4% for 31-40 harvested LNs, and 85.2% for ≥41 harvested LNs. Thirty harvested LNs was regarded as the optimal critical point of classification, considering the 5-year OS rate. The number of harvested LNs was selected as a significant prognostic factor in both univariate and multivariate analyses. The respective 3- and 5-year OS rates were 50.3% and 36.7% for <30 harvested LNs and 82.4% and 82.4% for ≥30 harvested LNs (p=0.003).
Thirty or more harvested LNs was a significant prognostic factor in patients with metastasis-negative LNs after curative esophagectomy for esophageal cancer. Therefore, the number of harvested LNs might be useful for predicting the LN metastasis status in esophageal cancer.
背景/目的：本研究旨在评估在根治性食管癌手术后淋巴结转移阴性的患者中，最佳的淋巴结（LNs）检出数量。
本研究纳入了 2005 年至 2017 年间接受根治性食管癌手术且诊断为淋巴结转移阴性的 61 例患者。
0-20 个淋巴结检出组、21-30 个淋巴结检出组、31-40 个淋巴结检出组和≥41 个淋巴结检出组的 5 年总生存率分别为 27.8%、35.7%、79.4%和 85.2%。考虑到 5 年 OS 率，30 个淋巴结检出被视为分类的最佳临界点。在单因素和多因素分析中，淋巴结检出数量均被选为显著的预后因素。<30 个淋巴结检出组的 3 年和 5 年 OS 率分别为 50.3%和 36.7%，≥30 个淋巴结检出组的 3 年和 5 年 OS 率分别为 82.4%和 82.4%（p=0.003）。
对于根治性食管癌手术后淋巴结转移阴性的患者，检出 30 个或更多的淋巴结是一个显著的预后因素。因此，淋巴结检出数量可能有助于预测食管癌的淋巴结转移状态。
